PD-L1 Mutations ID Patients Resistant to Immunotherapy 5 | GENengnews.com Programmed death ligand 1, or PD-L1, is a protein that conveys to the immune system not to kill a particular cell. In this new study, the research team reports that genetic alterations affecting a part of the PD-L1 gene increase the production of the protein, allowing cancer cells to escape detection by the immune system. "This is the first study to illustrate that a structural abnormality in the 3' untranslated region of the PD-L1 gene causes an abnormally high production of PD-L1 protein, consequently aiding cancer immune escape," explained lead ADDITIONAL CONTENT Live-Cell Analysis Handbook A comprehensive reference guide for real-time live-cell analysis inside the incubator and how it can redefine possibilities and workflows of cell biology. Download Now Image Source /Getty Images C ancer immunotherapy has ignited a firestorm of new drug compounds that target novel tumor markers that activate patients' immune system to destroy various cancer cell types. These therapies have provided remarkable success; however, they are expensive to produce and administer, with a percentage of patients showing little to no therapeutic efficacy. Now, scientists at Kyoto University have found unique genetic alterations that could indicate whether expensive immune checkpoint inhibitors would be effective for a particular patient.https://www.essenbioscience.com/en/forms/live-cell-analysis-handbook-request/ http://www.GENengnews.com